Table 2.

Major clinical trials of the short course radiotherapy (SCRT) combined with immunotherapy for LARC.

Study	Phase	No.	Features	Study design	Results
Wuhan	II	26	High risk+		pCR 46%
Averectal	II	40	III 91%		pCR 37.5% MPR 67.5%